TrialFrontiers in immunology2026

First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity.

Yue Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.